Paragonix, a medical technology company, has received FDA clearance for its pressure-controlled lung transplant system. The system, called Paragonix SherpaLung, aims to improve the transportation of donor lungs for transplantation. It uses a specially designed preservation vessel that regulates the pressure conditions inside the lung, allowing it to be transported for longer periods without damage.
The Paragonix SherpaLung system addresses one of the major challenges in lung transplantation, which is the limited time frame for transporting organs before they become unsuitable for transplantation. With the use of the system, lungs can be safely preserved and transported for up to 72 hours, which can significantly increase the availability of viable donor organs for transplantation.
The FDA clearance for Paragonix’s system is a significant development in the field of lung transplantation. By extending the time frame for transportation, the system has the potential to increase the success rate of lung transplants and improve patient outcomes. It also addresses the critical shortage of donor organs by allowing more lungs to be suitable for transplantation.
